CA 125 Test Market Size was valued at USD 0.9 Billion in 2023. The CA 125 Test market industry is projected to grow from USD 0.95 Billion in 2024 to USD 1.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.97% during the forecast period (2024 - 2032). Increased cancer prevalence and increased need for cancer detection and treatment, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The prevalence of ovarian cancer is predicted to rise, and early detection and treatment are expected to become more important. Of all gynecologic cancers, ovarian cancer had the greatest fatality rate as of 2018. In the U.S., it caused approximately 14,000 fatalities in 2018. Generic signs of the illness include bloating, irregular periods, vaginal bleeding, indigestion, and exhaustion, among others. The lack of identifiable symptoms makes early disease detection more challenging.
The prognosis for diseases is still bleak because most patients only receive advanced-stage diagnoses. Therefore, there is a critical need for in-depth study of disease biology to create potent therapeutic choices with the intention of overcoming resistance and reducing toxicity. Additional biomarker research may help identify patients who require a maintenance strategy. The market is anticipated to be driven by elements including an increase in government initiatives and increased financing for ovarian cancer research. For instance, the Ovarian Cancer Research Alliance (OCRA), a non-profit group, focuses on ovarian cancer research and development. It funds a number of research initiatives aimed at identifying and treating this condition.
According to the World Health Organisation (WHO), high-income countries have five-year survival rates for breast cancer that are above 90%, compared to 66% in India and 40% in South Africa. Blood tests called CA 125 tests are used to find some cancer markers that may help with breast cancer diagnosis. Breast cancer tumour markers can be used for screening, tracking cancer progression, spotting recurrence, and tracking therapy effectiveness. Therefore, the growth of the CA 125 test Market during the projection period is being driven by the rising utilisation of tumour markers for breast cancer.
According to the American Cancer Society, there will be 21,750 new cases of ovarian cancer in women in 2020, and 13,940 of those cases will result in death. The market is expected to expand over the course of the projected period as a result of increased ovarian cancer awareness in developed nations, simple accessibility, and reasonably priced test costs. On the other hand, it is projected that the market would soon be hampered by the low level of awareness of ovarian cancer in developing and undeveloped nations. The high cost of testing equipment restricts industry growth. Surveys show that the Covid-19 outbreak has caused a 90% reduction in the number of diagnostic facilities. The number of patients entering hospitals and clinics has fallen due to the increased risk of infection, which has resulted in a decline in the rates of diagnosis and treatment. It is projected that the growth of the CA 125 Test Market during the projection period would be adversely affected in the short term by labour shortages and transportation problems affecting the business community. Thus, driving the CA 125 Test market revenue.
The CA 125 Test market segmentation, based on Device & Accessory, includes Spectrometer, Analyzer, Sample Collection Tubes, Otopic Labelled Peptides, and Others. Spectrometer segment dominated the market in 2022. Spectrometry is the study of reactions, measurements of radiation wavelength and strength, and interactions between light and matter. Clinical mass spectrometry use the mass spectrometry technology for diagnostic purposes. Medical labs employ clinical mass spectrometry to determine the presence of biomarkers or enzymes, detect metabolic issues, and do toxicological testing.
The CA 125 Test market segmentation, based on Indication, includes Cancer, Uterine Fibroids, Endometriosis, Liver Disease, and Others. Cancer segment dominated the market in 2022. A higher risk of uterine cancer is not associated with uterine fibroids, also known as leiomyomas or myomas, and they seldom develop into cancer. In the illness known as endometriosis, tissue that normally surrounds the uterus begins to protrude outside of it. Similar to uterine tissue during your period, this tissue breaks down and bleeds at the conclusion of the cycle. However, there is nowhere for this blood to go. The tissues in the vicinity could swell or itch.
The CA 125 Test market segmentation, based on End User, includes Hospital & Clinic and Diagnostic Center. Diagnostic center segment dominated the CA 125 Test market in 2022.While diagnostic centres might want to maintain normal hours, a clinic may be more likely to provide emergency care after hours. It's possible that a clinic will charge less for therapy.
Figure 1: CA 125 Test Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
CA 125 Test Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America CA 125 Test Market dominated this market in 2022 (45.80%). This is because gynecologic diagnostics have performed well commercially in the United States. Other factors driving the market in this region include favourable government initiatives, an increase in healthcare spending, and the presence of important manufacturers.Further, the U.S. CA 125 Test market held the largest market share, and the Canada CA 125 Test market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CA 125 Test Market Share By Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe CA 125 Test market accounted for the healthy market share in 2022. The rising number of new cancer cases in Europe is one of the factors driving this region's expansion.Further, the German CA 125 Test market held the largest market share, and the U.K CA 125 Test market was the fastest growing market in the European region.
The Asia Pacific CA 125 Test market is expected to register significant growth from 2024 to 2032. This is because to things like general economic growth, better healthcare infrastructure, rising disposable money, and increased consumer awareness. Developing nations like India, China, and South Korea are anticipated to have substantial expansion in the ovarian cancer diagnostics market during the forecast period. Moreover, China’s CA 125 Test market held the largest market share and the Indian CA 125 Test market was the fastest growing market in the Asia-Pacific region.
CA 125 Test Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CA 125 Test market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, CA 125 Test industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the CA 125 Test industry to benefit clients and increase the market sector. In recent years, the CA 125 Test industry has offered some of the most significant advantages to medicine. Major players in the CA 125 Test market, including Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc., are attempting to increase market demand by investing in research and development Device & Accessorys.
Comprehensive genomic profiling tools are created and manufactured by Foundation Medicine with the goal of assisting doctors in making better treatment decisions. The company provides a thorough genomic profiling examination of the tumour genome to find clinically significant changes, potentially increasing the range of therapy options for patients. When LYNPARZA (olaparib) was first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer, Foundation Medicine's FoundationOne CDx, a comprehensive genomic profiling test, was declared by the company as having acquired FDA approval. Both germline and somatic BRCA1/2 mutations can be found using this test.
A manufacturer and distributor of medical equipment, reagents, and instruments is Becton Dickinson and Co. (BD). Syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools are among its main products. Researchers working in the field of life sciences, hospitals, clinics, the pharmaceutical sector, and the general public can all benefit from BD's products. throughout addition to Asia-Pacific, the corporation also markets its goods throughout the Americas, Europe, the Middle East, and Africa. BD's U.S. headquarters are in New Jersey. Becton, Dickinson and Company announced the acquisition of Cytognos in February 2022. The acquisition's terms were kept a secret. Becton now has exclusive access to assays licenced from the EuroFlow Consortium thanks to the purchase.
Key Companies in the CA 125 Test market include
CA 125 Test Industry Developments
July 2021: Becton, Dickinson and Company announced that Tepha, Inc. had been purchased. Tepha Inc. is a leading innovator and producer of specialised resorbable polymer technology. This acquisition encourages advancements in soft tissue regeneration and repair.
December 2020: VALIDATE® Tumour Markers have been discharged, according to LGC Maine Standards. This was done to satisfy the clinical laboratories' requirements for linearity and calibration verification. The Abbott Architect and Abbott Affinity systems are used in these labs.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.9 Billion |
| Market Size 2024 | USD 0.95 Billion |
| Market Size 2032 | USD 1.3 Billion |
| Compound Annual Growth Rate (CAGR) | 3.97% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Device & Accessory, Indication, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc. |
| Key Market Opportunities | Increasing emphasis on women healthcare |
| Key Market Dynamics | Increasing demand for cancer diagnosis and treatment and rising prevalence of cancer |
CA 125 Test Market Highlights:
Frequently Asked Questions (FAQ) :
The CA 125 Test market size was valued at USD 0.9 Billion in 2023.
The market is projected to grow at a CAGR of 3.97% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc.
The Spectrometer Device & Accessory dominated the market in 2022.
The Cancer Indication had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
